BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 15044431)

  • 21. Caspofungin in the treatment of oropharyngeal candidiasis.
    Garbino J; Lew D; Hirschel B; Rohner P
    Int J Clin Pract; 2003 Mar; 57(2):143-4. PubMed ID: 12661800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections.
    Groll AH; Walsh TJ
    Expert Opin Investig Drugs; 2001 Aug; 10(8):1545-58. PubMed ID: 11772269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Caspofungin: a potential cause of reversible severe thrombocytopenia.
    Lynch J; Wong-Beringer A
    Pharmacotherapy; 2004 Oct; 24(10):1408-11. PubMed ID: 15628837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Caspofungin in the treatment of azole-refractory esophageal candidiasis in kidney transplant recipients.
    Veroux M; Macarone M; Fiamingo P; Cappello D; Gagliano M; Di Mare M; Vizcarra D; Spataro M; Giuffrida G; Sorbello M; Severino V; Veroux P
    Transplant Proc; 2006 May; 38(4):1037-9. PubMed ID: 16757256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis.
    Colombo AL; Perfect J; DiNubile M; Bartizal K; Motyl M; Hicks P; Lupinacci R; Sable C; Kartsonis N
    Eur J Clin Microbiol Infect Dis; 2003 Aug; 22(8):470-4. PubMed ID: 12884068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial.
    DiNubile MJ; Lupinacci RJ; Strohmaier KM; Sable CA; Kartsonis NA
    J Crit Care; 2007 Sep; 22(3):237-44. PubMed ID: 17869975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Caspofungin.
    Deresinski SC; Stevens DA
    Clin Infect Dis; 2003 Jun; 36(11):1445-57. PubMed ID: 12766841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Caspofungin: first approved agent in a new class of antifungals.
    Johnson MD; Perfect JR
    Expert Opin Pharmacother; 2003 May; 4(5):807-23. PubMed ID: 12740003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.
    Pappas PG; Rotstein CM; Betts RF; Nucci M; Talwar D; De Waele JJ; Vazquez JA; Dupont BF; Horn DL; Ostrosky-Zeichner L; Reboli AC; Suh B; Digumarti R; Wu C; Kovanda LL; Arnold LJ; Buell DN
    Clin Infect Dis; 2007 Oct; 45(7):883-93. PubMed ID: 17806055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Echinocandin antifungal drugs.
    Denning DW
    Lancet; 2003 Oct; 362(9390):1142-51. PubMed ID: 14550704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resolution of multidrug-refractory oesophageal candidiasis in an AIDS patient after treatment with caspofungin.
    Sollima S; Corbellino M; Cicconi P; Piazza M; Viganò O; Antinori S
    AIDS; 2002 Jun; 16(9):1303-4. PubMed ID: 12045503
    [No Abstract]   [Full Text] [Related]  

  • 32. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome.
    Kartsonis N; Killar J; Mixson L; Hoe CM; Sable C; Bartizal K; Motyl M
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3616-23. PubMed ID: 16127030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Successful treatment with caspofungin of an invasive candidosis resistant to liposomal amphotericin B in a neutropenic patient].
    Rome A; André N; Michel A; Coze C; Gentet JC; Bernard JL
    Arch Pediatr; 2006 Dec; 13(12):1556-7. PubMed ID: 17049216
    [No Abstract]   [Full Text] [Related]  

  • 34. Caspofungin for invasive candidiasis at a tertiary care medical center.
    Zaas AK; Dodds Ashley ES; Alexander BD; Johnson MD; Perfect JR
    Am J Med; 2006 Nov; 119(11):993.e1-6. PubMed ID: 17071169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antifungal alternatives for invasive candidiasis refractory to caspofungin in liver transplant recipients: A report of two cases.
    Choukroun G; Thirion M; Lortholary O; Scatton O; Conti F; Calmus Y; Paugam A; Pène F
    Transplantation; 2006 Nov; 82(10):1385-6. PubMed ID: 17130792
    [No Abstract]   [Full Text] [Related]  

  • 36. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis.
    Villanueva A; Arathoon EG; Gotuzzo E; Berman RS; DiNubile MJ; Sable CA
    Clin Infect Dis; 2001 Nov; 33(9):1529-35. PubMed ID: 11588698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Candida albicans endocarditis treatment with caspofungin in an HIV-infected patient--case report and review of literature.
    Bacak V; Biocina B; Starcevic B; Gertler S; Begovac J
    J Infect; 2006 Jul; 53(1):e11-4. PubMed ID: 16274746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pharmacology and clinical use of caspofungin.
    Hope WW; Shoham S; Walsh TJ
    Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):263-74. PubMed ID: 17428155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, double-blind, prospective study of caspofungin vs. amphotericin B for the treatment of invasive candidiasis in newborn infants.
    Mohamed WA; Ismail M
    J Trop Pediatr; 2012 Feb; 58(1):25-30. PubMed ID: 21355042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Caspofungin versus amphotericin B for invasive candidiasis.
    Brown AL; Greig JR
    N Engl J Med; 2003 Mar; 348(13):1287-8; author reply 1287-8. PubMed ID: 12660396
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.